|
1
|
Frost G: The latency period of
mesothelioma among a cohort of British asbestos workers
(1978–2005). Br J Cancer. 109:1965–1973. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peto J, Decarli A, La Vecchia C, Levi F
and Negri E: The European mesothelioma epidemic. Br J Cancer.
79:666–672. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Myojin T, Azuma K, Okumura J and Uchiyama
I: Future trends of mesothelioma mortality in Japan based on a risk
function. Ind Health. 50:197–204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Keshava HB, Tang A, Siddiqui HU, Raja S,
Raymond DP, Bribriesco A, Stevenson J, Murthy SC and Ahmad U:
Largely Unchanged annual incidence and overall survival of pleural
mesothelioma in the USA. World J Surg. 43:3239–3247. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Joshi TK and Gupta RK: Asbestos in
developing countries: Magnitude of risk and its practical
implications. Int J Occup Med Environ Health. 17:179–185.
2004.PubMed/NCBI
|
|
6
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S,
Manegold C, et al: Phase III study of pemetrexed in combination
with cisplatin versus cisplatin alone in patients with malignant
pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu KL, Tsai YM, Lien CT, Kuo PL and Hung
AJ: The roles of MicroRNA in lung cancer. Int J Mol Sci.
20:E16112019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen SN, Chang R, Lin LT, Chern CU, Tsai
HW, Wen ZH, Li YH, Li CJ and Tsui KH: MicroRNA in ovarian cancer:
Biology, pathogenesis, and therapeutic opportunities. Int J Environ
Res Public Health. 16:E15102019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Banelli B, Forlani A, Allemanni G,
Morabito A, Pistillo MP and Romani M: MicroRNA in glioblastoma: An
overview. Int J Genomics. 2017:76390842017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Amatya VJ, Mawas AS, Kushitani K, Mohi
El-Din MM and Takeshima Y: Differential microRNA expression
profiling of mesothelioma and expression analysis of miR-1 and
miR-214 in mesothelioma. Int J Oncol. 48:1599–1607. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Song Y, Wang P, Zhao W, Yao Y, Liu X, Ma
J, Xue Y and Liu Y: miR-18a regulates the proliferation, migration
and invasion of human glioblastoma cell by targeting neogenin. Exp
Cell Res. 324:54–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang W, Lei C, Fan J and Wang J: miR-18a
promotes cell proliferation of esophageal squamous cell carcinoma
cells by increasing cylin D1 via regulating PTEN-PI3K-AKT-mTOR
signaling axis. Biochem Biophys Res Commun. 477:144–149. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao H, Liu Y, Liang P, Wang B, Tan H,
Zhang Y, Gao X and Gao J: TP53TG1 enhances cisplatin sensitivity of
non-small cell lung cancer cells through regulating miR-18a/PTEN
axis. Cell Biosci. 8:232018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Usami N, Fukui T, Kondo M, Taniguchi T,
Yokoyama T, Mori S, Yokoi K, Horio Y, Shimokata K, Sekido Y and
Hida T: Establishment and characterization of four malignant
pleural mesothelioma cell lines from Japanese patients. Cancer Sci.
97:387–394. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gebäck T, Schulz MM, Koumoutsakos P and
Detmar M: TScratch: A novel and simple software tool for automated
analysis of monolayer wound healing assays. Biotechniques.
46:265–274. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ventura A and Jacks T: MicroRNAs and
cancer: Short RNAs go a long way. Cell. 136:586–591. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hanna J, Hossain GS and Kocerha J: The
potential for microRNA therapeutics and clinical research. Front
Genet. 10:4782019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Truini A, Coco S, Genova C, Mora M, Dal
Bello MG, Vanni I, Alama A, Rijavec E, Barletta G, Biello F, et al:
Prognostic and therapeutic implications of MicroRNA in malignant
pleural mesothelioma. Microrna. 5:12–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lo Russo G, Tessari A, Capece M, Galli G,
de Braud F, Garassino MC and Palmieri D: MicroRNAs for the
diagnosis and management of malignant pleural mesothelioma: A
literature review. Front Oncol. 8:6502018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Johnson TG, Schelch K, Cheng YY, Williams
M, Sarun KH, Kirschner MB, Kao S, Linton A, Klebe S, McCaughan BC,
et al: Dysregulated expression of the microRNA miR-137 and its
target YBX1 contribute to the invasive characteristics of malignant
pleural mesothelioma. J Thorac Oncol. 13:258–272. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Williams M, Kirschner MB, Cheng YY, Hanh
J, Weiss J, Mugridge N, Wright CM, Linton A, Kao SC, Edelman JJ, et
al: miR-193a-3p is a potential tumor suppressor in malignant
pleural mesothelioma. Oncotarget. 6:23480–23495. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mawas AS, Amatya VJ, Suzuki R, Kushitani
K, Mohi El-Din MM and Takeshima Y: PIM1 knockdown inhibits cell
proliferation and invasion of mesothelioma cells. Int J Oncol.
50:1029–1034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suzuki R, Amatya VJ, Kushitani K, Kai Y,
Kambara T and Takeshima Y: miR-182 and miR-183 promote cell
proliferation and invasion by targeting FOXO1 in mesothelioma.
Front Oncol. 8:4462018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He T, McColl K, Sakre N, Chen Y, Wildey G
and Dowlati A: Post-transcriptional regulation of PIAS3 expression
by miR-18a in malignant mesothelioma. Mol Oncol. 12:2124–2135.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schelch K, Kirschner MB, Williams M, Cheng
YY, van Zandwijk N, Grusch M and Reid G: A link between the
fibroblast growth factor axis and the miR-16 family reveals
potential new treatment combinations in mesothelioma. Mol Oncol.
12:58–73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van Zandwijk N, Pavlakis N, Kao SC, Linton
A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey
DL, et al: Safety and activity of microRNA-loaded minicells in
patients with recurrent malignant pleural mesothelioma: A
first-in-man, phase 1, open-label, dose-escalation study. Lancet
Oncol. 18:1386–1396. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roussel MF: The INK4 family of cell cycle
inhibitors in cancer. Oncogene. 18:5311–5317. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bartkova J, Rajpert-De Meyts E, Skakkebaek
NE, Lukas J and Bartek J: Deregulation of the G1/S-phase control in
human testicular germ cell tumours. APMIS. 111:252–265; discussion
265-256. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin S, Wang MJ and Tseng KY:
Polypyrimidine tract-binding protein induces p19(Ink4d) expression
and inhibits the proliferation of H1299 cells. PLoS One.
8:e582272013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wei X, Gao M, Ahmed Y, Gao M, Liu W, Zhang
Y, Xie X, Zhao Q, Wang H and Gu K: MicroRNA-362-5p enhances the
cisplatin sensitivity of gastric cancer cells by targeting
suppressor of zeste 12 protein. Oncol Lett. 18:1607–1616.
2019.PubMed/NCBI
|
|
33
|
Xue M, Li G, Sun P, Zhang D, Fang X and Li
W: MicroRNA-613 induces the sensitivity of gastric cancer cells to
cisplatin through targeting SOX9 expression. Am J Transl Res.
11:885–894. 2019.PubMed/NCBI
|
|
34
|
Shi SB, Wang M, Tian J, Li R, Chang CX and
Qi JL: MicroRNA 25, microRNA 145, and microRNA 210 as biomarkers
for predicting the efficacy of maintenance treatment with
pemetrexed in lung adenocarcinoma patients who are negative for
epidermal growth factor receptor mutations or anaplastic lymphoma
kinase translocations. Transl Res. 170:1–7. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Moody HL, Lind MJ and Maher SG:
MicroRNA-31 regulates chemosensitivity in malignant pleural
mesothelioma. Mol Ther Nucleic Acids. 8:317–329. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cioce M, Ganci F, Canu V, Sacconi A, Mori
F, Canino C, Korita E, Casini B, Alessandrini G, Cambria A, et al:
Protumorigenic effects of mir-145 loss in malignant pleural
mesothelioma. Oncogene. 33:5319–5331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yamamoto K, Seike M, Takeuchi S, Soeno C,
Miyanaga A, Noro R, Minegishi Y, Kubota K and Gemma A: miR-379/411
cluster regulates IL-18 and contributes to drug resistance in
malignant pleural mesothelioma. Oncol Rep. 32:2365–2372. 2014.
View Article : Google Scholar : PubMed/NCBI
|
